Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation.

Tabrizi M, Neupane D, Elie SE, Shankaran H, Juan V, Zhang S, Hseih S, Fayadat-Dilman L, Zhang D, Song Y, Ganti V, Judo M, Spellman D, Seghezzi W, Escandon E.

AAPS J. 2019 Mar 13;21(3):39. doi: 10.1208/s12248-019-0304-3.

PMID:
30868312
2.

Erratum. Engineering Glucose Responsiveness Into Insulin. Diabetes 2018;67:299-308.

Kaarsholm NC, Lin S, Yan L, Kelly T, van Heek M, Mu J, Wu M, Dai G, Cui Y, Zhu Y, Carballo-Jane E, Reddy V, Zafian P, Huo P, Shi S, Antochshuk V, Ogawa A, Liu F, Souza SC, Seghezzi W, Duffy JL, Erion M, Nargund RP, Kelley DE.

Diabetes. 2018 May;67(5):1030. doi: 10.2337/db18-er05a. Epub 2018 Feb 27. No abstract available.

3.

Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.

Bhagwat B, Cherwinski H, Sathe M, Seghezzi W, McClanahan TK, de Waal Malefyt R, Willingham A.

J Immunol Methods. 2018 May;456:7-14. doi: 10.1016/j.jim.2018.02.003. Epub 2018 Feb 8.

4.

Quantitation of a Therapeutic Antibody in Serum Using Intact Sequential Affinity Capture, Trypsin Digestion, and LC-MS/MS.

Vasicek LA, Spellman DS, Hsieh S, Seghezzi W, Zhang S, Santostefano M, Bateman KP.

Anal Chem. 2018 Jan 2;90(1):866-871. doi: 10.1021/acs.analchem.7b03716. Epub 2017 Dec 20.

PMID:
29206445
5.

Engineering Glucose Responsiveness Into Insulin.

Kaarsholm NC, Lin S, Yan L, Kelly T, van Heek M, Mu J, Wu M, Dai G, Cui Y, Zhu Y, Carballo-Jane E, Reddy V, Zafian P, Huo P, Shi S, Antochshuk V, Ogawa A, Liu F, Souza SC, Seghezzi W, Duffy JL, Erion M, Nargund RP, Kelley DE.

Diabetes. 2018 Feb;67(2):299-308. doi: 10.2337/db17-0577. Epub 2017 Nov 2. Erratum in: Diabetes. 2018 Feb 27;:.

6.

Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters.

Nguyen TV, Ukairo O, Khetani SR, McVay M, Kanchagar C, Seghezzi W, Ayanoglu G, Irrechukwu O, Evers R.

Drug Metab Dispos. 2015 May;43(5):774-85. doi: 10.1124/dmd.114.061317. Epub 2015 Mar 4.

PMID:
25739975
7.

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H.

Infect Immun. 2015 Feb;83(2):822-31. doi: 10.1128/IAI.02897-14. Epub 2014 Dec 8.

8.

Generic automated method for liquid chromatography-multiple reaction monitoring mass spectrometry based monoclonal antibody quantitation for preclinical pharmacokinetic studies.

Zhang Q, Spellman DS, Song Y, Choi B, Hatcher NG, Tomazela D, Beaumont M, Tabrizifard M, Prabhavalkar D, Seghezzi W, Harrelson J, Bateman KP.

Anal Chem. 2014 Sep 2;86(17):8776-84. doi: 10.1021/ac5019827. Epub 2014 Aug 14.

PMID:
25010922
9.

The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.

Labroli MA, Dwyer MP, Shen R, Popovici-Muller J, Pu Q, Wyss D, McCoy M, Barrett D, Davis N, Seghezzi W, Shanahan F, Taricani L, Beaumont M, Malinao MC, Parry D, Guzi TJ.

Bioorg Med Chem. 2014 Apr 1;22(7):2303-10. doi: 10.1016/j.bmc.2014.02.007. Epub 2014 Feb 15.

PMID:
24588962
10.

Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.

Huang X, Cheng CC, Fischmann TO, Duca JS, Richards M, Tadikonda PK, Reddy PA, Zhao L, Siddiqui MA, Parry D, Davis N, Seghezzi W, Wiswell D, Shipps GW Jr.

Bioorg Med Chem Lett. 2013 May 1;23(9):2590-4. doi: 10.1016/j.bmcl.2013.02.108. Epub 2013 Mar 7.

PMID:
23535330
11.

IL-10 elicits IFN╬│-dependent tumor immune surveillance.

Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, Sheppard C, Hong K, Cutler C, Turner S, LaFace D, Kleinschek M, Judo M, Ayanoglu G, Langowski J, Gu D, Paporello B, Murphy E, Sriram V, Naravula S, Desai B, Medicherla S, Seghezzi W, McClanahan T, Cannon-Carlson S, Beebe AM, Oft M.

Cancer Cell. 2011 Dec 13;20(6):781-96. doi: 10.1016/j.ccr.2011.11.003.

12.

Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.

Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, Taricani L, Wiswell D, Seghezzi W, Penaflor E, Bhagwat B, Wang W, Gu D, Hsieh Y, Lee S, Liu M, Parry D.

Mol Cancer Ther. 2011 Apr;10(4):591-602. doi: 10.1158/1535-7163.MCT-10-0928. Epub 2011 Feb 14.

13.

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.

Dwyer MP, Paruch K, Labroli M, Alvarez C, Keertikar KM, Poker C, Rossman R, Fischmann TO, Duca JS, Madison V, Parry D, Davis N, Seghezzi W, Wiswell D, Guzi TJ.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):467-70. doi: 10.1016/j.bmcl.2010.10.113. Epub 2010 Oct 27.

PMID:
21094608
14.

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.

Labroli M, Paruch K, Dwyer MP, Alvarez C, Keertikar K, Poker C, Rossman R, Duca JS, Fischmann TO, Madison V, Parry D, Davis N, Seghezzi W, Wiswell D, Guzi TJ.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):471-4. doi: 10.1016/j.bmcl.2010.10.114. Epub 2010 Oct 28.

PMID:
21094607
15.

Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.

Zhao L, Zhang Y, Dai C, Guzi T, Wiswell D, Seghezzi W, Parry D, Fischmann T, Siddiqui MA.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7216-21. doi: 10.1016/j.bmcl.2010.10.105. Epub 2010 Oct 26.

PMID:
21074424
16.

Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.

Sheth PR, Shipps GW Jr, Seghezzi W, Smith CK, Chuang CC, Sanden D, Basso AD, Vilenchik L, Gray K, Annis DA, Nickbarg E, Ma Y, Lahue B, Herbst R, Le HV.

Biochemistry. 2010 Sep 28;49(38):8350-8. doi: 10.1021/bi1005283.

PMID:
20718440
17.

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, Keertikar K, Knutson C, McKittrick B, Rivera J, Rossman R, Tucker G, Fischmann T, Hruza A, Madison V, Nomeir AA, Wang Y, Kirschmeier P, Lees E, Parry D, Sgambellone N, Seghezzi W, Schultz L, Shanahan F, Wiswell D, Xu X, Zhou Q, James RA, Paradkar VM, Park H, Rokosz LR, Stauffer TM, Guzi TJ.

ACS Med Chem Lett. 2010 May 17;1(5):204-8. doi: 10.1021/ml100051d. eCollection 2010 Aug 12.

18.

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM.

Mol Cancer Ther. 2010 Aug;9(8):2344-53. doi: 10.1158/1535-7163.MCT-10-0324. Epub 2010 Jul 27.

19.

Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.

Lahue BR, Ma Y, Shipps GW Jr, Seghezzi W, Herbst R.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3405-9. doi: 10.1016/j.bmcl.2009.05.040. Epub 2009 May 18.

PMID:
19481450
20.

Structure-guided discovery of cyclin-dependent kinase inhibitors.

Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V.

Biopolymers. 2008 May;89(5):372-9.

PMID:
17937404
21.

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, Keertikar K, Knutson C, McKittrick B, Rivera J, Rossman R, Tucker G, Fischmann TO, Hruza A, Madison V, Nomeir AA, Wang Y, Lees E, Parry D, Sgambellone N, Seghezzi W, Schultz L, Shanahan F, Wiswell D, Xu X, Zhou Q, James RA, Paradkar VM, Park H, Rokosz LR, Stauffer TM, Guzi TJ.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6220-3. Epub 2007 Sep 8.

PMID:
17904841
22.

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.

Dwyer MP, Paruch K, Alvarez C, Doll RJ, Keertikar K, Duca J, Fischmann TO, Hruza A, Madison V, Lees E, Parry D, Seghezzi W, Sgambellone N, Shanahan F, Wiswell D, Guzi TJ.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6216-9. Epub 2007 Sep 8.

PMID:
17904366
23.

AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer.

Jiang Y, Zhang Y, Lees E, Seghezzi W.

Oncogene. 2003 Nov 13;22(51):8293-301.

PMID:
14614453
24.

The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation.

Walter AO, Seghezzi W, Korver W, Sheung J, Lees E.

Oncogene. 2000 Oct 5;19(42):4906-16.

25.

Regulation of G1/S transition in mammalian cells

Guevara C, Korver W, Mahony D, Parry D, Seghezzi W, Shanahan F, Lees E.

Kidney Int. 1999 Oct;56(4):1181-92. No abstract available.

26.

A novel growth- and cell cycle-regulated protein, ASK, activates human Cdc7-related kinase and is essential for G1/S transition in mammalian cells.

Kumagai H, Sato N, Yamada M, Mahony D, Seghezzi W, Lees E, Arai K, Masai H.

Mol Cell Biol. 1999 Jul;19(7):5083-95.

27.
28.

Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells.

Seghezzi W, Chua K, Shanahan F, Gozani O, Reed R, Lees E.

Mol Cell Biol. 1998 Aug;18(8):4526-36.

29.

Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis.

Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R.

Genes Dev. 1998 May 15;12(10):1409-14.

30.

Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II.

Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E.

Oncogene. 1996 Jun 20;12(12):2631-40.

PMID:
8700522
31.

Probing the membrane topology of Candida tropicalis cytochrome P450.

Sanglard D, Sengstag C, Seghezzi W.

Eur J Biochem. 1993 Sep 1;216(2):477-85.

32.

Identification and characterization of additional members of the cytochrome P450 multigene family CYP52 of Candida tropicalis.

Seghezzi W, Meili C, Ruffiner R, Kuenzi R, Sanglard D, Fiechter A.

DNA Cell Biol. 1992 Dec;11(10):767-80.

PMID:
1457045
33.

Supplemental Content

Loading ...
Support Center